

Michael J. Isaacs, MD

Dawes Fretzin Clinical Research Group, LLC

7910 North Shadeland Avenue
Indianapolis, IN 46250
Phone (317) 516-5030
Fax (317) 516-5031
Email: michaelfcrg@gmail.com

Dawes Fretzin Dermatology Group, LLC

7910 North Shadeland Avenue
Indianapolis, IN 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Indiana University (Indianapolis, IN)
Dermatology Residency, 2017-2020

Indiana University School of Medicine (Indianapolis, IN)
Internal Medicine Residency, 2016-2017

Indiana University School of Medicine (Indianapolis, IN)
Medical Doctorate, 2016

University of Notre Dame (South Bend, IN)
Bachelor of Science in Science Pre-Professional Studies, 2012

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Sub-Investigator, October 2022-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, – August 2020-Present

Honors and Awards

2016 Alpha Omega Alpha Honor Medical Society Graduate
2016 I.U.S.M. Department of Dermatology Award
2015 I.U.S.M. Dean's Council Annual Chizek Family Foundation Scholarship
2013 University of Notre Dame Dooley Society Medical Mission Scholarship
2012 Lawrence H. Baldinger Award
2008 Lilly Endowment Community Scholarship



17-JUN-2026

License/Certifications

Indiana State License # 01083290A
American Board of Dermatology, 2020
ACLS Certification
CITI GCP Certification

Michael J. Isaacs, MD

Articles and Publications

- Isaacs, M**, Veerkamp, P, Somani, A. "Small Intestinal Submucosa Matrix as a Novel Therapy for Wounds in Dystrophic Epidermolysis Bullosa." *Dermatologic Surgery*. Published Online Ahead of Print: December 24, 2018 (DOI: 10.1097/DSS.0000000000001731).
- Isaacs, M**, Cardones, A, Rahnama-Moghadam, S. "DRESS Syndrome: Clinical Myths and Pearls." *Cutis*. November 2018; 102(5):322-326.
- Veerkamp, P, **Isaacs, M**, Somani, A. "Small Intestinal Submucosal Matrix as a Novel Reconstructive Option for Large Scrotal Defects." *Dermatologic Surgery*. February 2018; 44(2):318-321.
- Siesky B, Harris A, Carr J, Verticchio Vercellin A, Hussain RM, **Isaacs, M**, et al. "Reductions in Retrobulbar and Retinal Capillary Blood Flow Strongly Correlate With Changes in Optic Nerve Head and Retinal Morphology Over 4 Years in Open-angle Glaucoma Patients of African Descent Compared With Patients of European Descent." *Journal of Glaucoma*. September 2016; 25(9):750-7.
- Isaacs, M**, Strausburg, M, Mousdicas, N. "Pediatric Positional Sitting Dermatitis: A New Form of Pediatric Contact Dermatitis" *Pediatric Dermatology*. May 2016; 33(3):e226-7.
- Isaacs, M**, Hossler, E. "Cutaneous Leishmaniasis" (Dermatopathology Diagnosis). *Cutis*. December 2015; 96(6):367, 408-9.
- Isaacs, M**. "One Step at a Time." *Reflections*. Indiana University School of Medicine Peer-Reviewed Creative Art Journal. August 2015: 28-29.
- Isaacs, M**. "Medical Fruits of Labor." *The Linacre Quarterly*. August 2015; 82(3):193-6.
- Euler, C, **Isaacs, M**, Simic, D, Van Vleet, T, Gillham, S, Peden, M. "Evaluation of RNA Amplification Efficiency to Determine Optimal RNA Concentration Ranges from Formalin-Fixed Paraffin-Embedded Rodent Tissues for Gene Expression Analysis." *Journal of Histotechnology*. April 2015; 38(1): 2-8.
- Isaacs, M**, Tharp, M. "Antihistamines." *Comprehensive Dermatologic Drug Therapy, 4th Edition*, edited by Stephen Wolverton. Accepted for Publication. Anticipated Book Release Date: Spring 2020.
- Isaacs, M**. "Case Presentation – Granulomatous Cheilitis." *2018 Indiana Academy of Dermatology Fall Meeting*, November 2018, Indianapolis, IN.
- Isaacs, M**. "Off-Label Uses of Apremilast." *Indiana University Department of Dermatology Grand Rounds*, September 2018, Indianapolis, IN.
- Isaacs, M**. "Systemic Therapies for Chronic Pruritus." *Indiana University Department of Dermatology Grand Rounds*, March 2017, Indianapolis, IN.
- Isaacs, M**. "Case Presentation – Advanced Pretibial Myxedema." *2017 Indiana Academy of Dermatology Fall Meeting*, November 2017, Indianapolis, IN.

Michael J. Isaacs, MD

Articles and Publications - continued

Isaacs, M. "Case Presentation – Burn-Induced Pemphigus Foliaceus." *2018 Indiana Academy of Dermatology Spring Meeting*, May 2018, Indianapolis, IN.

Isaacs, M, Miller, J. "Angiokeratoma formation temporally associated with a course of tigecycline." *2016 Annual Meeting of the American Academy of Dermatology*, March 2016, Washington, D.C.

Isaacs, M, Strausburg, M, Mousdicas, N. "Crural papouts dermatitis: a new form of pediatric posterior thigh dermatitis." *2016 Annual Meeting of the American Academy of Dermatology*, March 2016, Washington, D.C.

Isaacs, M, Mousdicas, N. "Lucky Luke sign: clothing dermatitis in an adult." *2015 I.U.S.M. Alumni Research Poster Symposium*, May 2015, Indianapolis, IN.

Isaacs, M, Downing, B, Ingram, D. "Neurofibromatosis insufficiency results in aneurysms via increased reactive oxygen species." *Indiana Clinical and Translational Sciences Institute Annual Meeting*, September 2013, Indianapolis, IN.

Isaacs, M, Downing, B, Ingram, D. "Neurofibromatosis insufficiency results in aneurysms via increased reactive oxygen species." *4th Annual Student Research Program in Academic Medicine*, July 2013, Indianapolis, IN.

Euler, C, Simic, D, **Isaacs, M**, Gillham, S, Sanderson, T, Bunch, R, Peden, W, Van Vleet, T. "Time Course Evaluation of RNA Integrity from Rodent Tissues." *Bristol-Myers Research and Development Symposium*, April 2011, Princeton, NJ.

Isaacs, M. "Defining Success." Presented at St. John the Evangelist Catholic Church "Be A Man" Fall Series, November 2018, Indianapolis, IN.

Isaacs, M. "Living Out A Catholic Marriage." Presented at 2015 St. John the Evangelist Catholic Church "Marriage Enrichment Forum", September 2015, Indianapolis, IN.

Isaacs, M. "Notre Dame to El Salvador: One Student's Journey." Presented at 2013 University of Notre Dame Dooley Society Annual Scholarship Meeting, August 2013, Notre Dame, IN.

Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

Sponsor	Protocol	Indication	Role	Phase	Date of COV
UPENN	Acne	Acne	Sub-I	4	16-Apr-25
Sanofi	VBE00001	Acne	Sub-I	1/2	24-Feb-26
Pfizer	B7981015	Alopecia Areata	Sub-I	2b/3	03-Aug-21
Reistone	RSJ10521	Alopecia Areata	Sub-I	2	26-Aug-21
AnaptysBio	ANB030-201	Alopecia Areata	Sub-I	2	22-Mar-23
Horizon	HZNP-DAX-201	Alopecia Areata	Sub-I	2a	28-Mar-23
Concert	CP543.3001	Alopecia Areata	Sub-I	3	13-Jul-23

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Arena	APD334-205	Alopecia Areata	Sub-I	2	30-Aug-23
Pfizer	B7981031	Alopecia Areata	Sub-I	1	17-Oct-23
Inmagene	IMG-007-002	Alopecia Areata	Sub-I	1b/2a	28-Jun-24
Pfizer	B7981032	Alopecia Areata	Sub-I	3	01-Aug-24
Aslan	ASLAN003-004	Alopecia Areata	Sub-I	2a	12-Aug-24
Sanofi	DRI18180	Alopecia Areata	Sub-I	2	10-Feb-25
Lilly	I4V-MC-JAIR	Alopecia Areata	Sub-I	3	13-Mar-25
Adelphi	AG9909	Alopecia Areata	Sub-I	OBS	15-Apr-26
Concert	CP543.5001	Alopecia Areata	Sub-I	3	28-Apr-26
Abbvie	M24-725	Alopecia Areata	Sub-I	3	ONGOING
CorEvitas	AA-565	Alopecia Areata	Sub-I	OBS	ONGOING
Pfizer	B7981027	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981028	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981094	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981110	Alopecia Areata	Sub-I	3	ONGOING
DrenBlo	DR-01-AIM-001	Alopecia Areata	Sub-I	1b	ONGOING
HCW Biologics	HCWALO101	Alopecia Areata	Sub-I	1b	ONGOING
Lilly	I4V-MC-JAIO	Alopecia Areata	Sub-I	3	ONGOING
Sun Pharma	CP543.3101	Alopecia Areata	Sub-I	3	ONGOING
Pelage	PP405-2001	Androgenetic Alopecia	Sub-I	2a	24-Nov-25
Pelage	PP405-2002	Androgenetic Alopecia	Sub-I	2/3	ONGOING
Veradermics	250-13951-302	Androgenetic Alopecia	Sub-I	3	ONGOING
Veradermics	250-13951-306	Androgenetic Alopecia	Sub-I	3	ONGOING
Pfizer	B7451050	Atopic Dermatitis	Sub-I	3b	12-Aug-21
BMX	BMX-DERM-01	Atopic Dermatitis	Sub-I	1/2	24-Aug-21
Pfizer	C3941002	Atopic Dermatitis	Sub-I	2a	15-Nov-21
Janssen	77474462ADM2003	Atopic Dermatitis	Sub-I	2a	06-Apr-22
Abbvie	M19-850	Atopic Dermatitis	Sub-I	3b	21-Apr-22
Janssen	77474462ADM2001	Atopic Dermatitis	Sub-I	3	16-May-22
Lilly	F1P-MC-KFAD	Atopic Dermatitis	Sub-I	1	21-Jun-22
BMS	IM011-005	Atopic Dermatitis	Sub-I	2	01-Aug-22
Dermira	DRM06-AD17	Atopic Dermatitis	Sub-I	3	24-Aug-22
BMS	IM018-005	Atopic Dermatitis	Sub-I	2	20-Sep-22
Celgene	CC-93538-AD-001	Atopic Dermatitis	Sub-I	2	07-Dec-22
Connect	CBP-201-WW004	Atopic Dermatitis	Sub-I	3	30-Dec-22
LEO	LP0162-1337	Atopic Dermatitis	Sub-I	3	27-Jan-23
Galderma	RD.06.SPR.118161	Atopic Dermatitis	Sub-I	3	13-Feb-23
GSK	215253	Atopic Dermatitis	Sub-I	1b	13-Jun-23
Arcutis	ARQ-151-313	Atopic Dermatitis	Sub-I	3	11-Jul-23
Pfizer	C3941005	Atopic Dermatitis	Sub-I	2b	01-Aug-23
OM1	DataDerm	Atopic Dermatitis	Sub-I	OBS	19-Aug-23
Evommune	EVO101-AD001	Atopic Dermatitis	Sub-I	2a	29-Aug-23
Alumis	ESK-001-006	Atopic Dermatitis	Sub-I	2	08-Sep-23

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
DermTech	20-03	Atopic Dermatitis	Sub-I	4	24-Oct-23
Acrotech	MEDI-MM36-301	Atopic Dermatitis	Sub-I	3	20-Nov-23
Evidera	EVA-25835	Atopic Dermatitis	Sub-I	OBS	15-Dec-23
Galderma	RD.06.SPR.118380	Atopic Dermatitis	Sub-I	2	21-Dec-23
Aslan	ASLAN004-003	Atopic Dermatitis	Sub-I	2b	04-Jan-24
Aclaris	ATI-1777-AD-202	Atopic Dermatitis	Sub-I	2b	06-Feb-24
Alumis	ESK-001-007	Atopic Dermatitis	Sub-I	2	13-Feb-24
TrialSpark	ASN008-201	Atopic Dermatitis	Sub-I	2	14-Feb-24
Cara	CR845-310501	Atopic Dermatitis	Sub-I	3	07-Mar-24
Kymab	KY1005-CT05	Atopic Dermatitis	Sub-I	2b	02-May-24
Rapt	RPT193-02	Atopic Dermatitis	Sub-I	2	07-Jun-24
Incyte	INCB18424-305	Atopic Dermatitis	Sub-I	3	26-Jun-24
Acrotech	MEDI-MM36-302	Atopic Dermatitis	Sub-I	3	16-Jul-24
Biosion	BSI-045B-002	Atopic Dermatitis	Sub-I	2a	18-Jul-24
Abbvie	M16-049	Atopic Dermatitis	Sub-I	2b	29-Oct-24
Abbvie	M23-696	Atopic Dermatitis	Sub-I	3b/4	29-Oct-24
Taro	RXLC-2118	Atopic Dermatitis	Sub-I	4	04-Dec-24
Incyte	INCB18424-902	Atopic Dermatitis	Sub-I	4	05-Feb-25
Pfizer	B7451015	Atopic Dermatitis	Sub-I	3	25-Mar-25
Lilly	J2T-MC-KGBO	Atopic Dermatitis	Sub-I	3b	01-Apr-25
Lilly	J2T-MC-KGBP	Atopic Dermatitis	Sub-I	3b	02-Apr-25
Dermira	DRM06-AD07	Atopic Dermatitis	Sub-I	3	09-Apr-25
Amgen	20210144	Atopic Dermatitis	Sub-I	3	29-Apr-25
Galderma	RD.06.SPR.118126	Atopic Dermatitis	Sub-I	2	11-Jun-25
Abbvie	M24-601	Atopic Dermatitis	Sub-I	3b/4	12-Jun-25
LEO	LP0145-2240	Atopic Dermatitis	Sub-I	2b	25-Jun-25
Apollo	AP43CP03	Atopic Dermatitis	Sub-I	2	04-Nov-25
CastleBio Science	CBI_2021_ISD_DevVal_001	Atopic Dermatitis	Sub-I	4	02-Dec-25
Galderma	RD.06.SPR.118163	Atopic Dermatitis	Sub-I	3	20-Jan-26
Sanofi	EFC17561	Atopic Dermatitis	Sub-I	3	03-Feb-26
Abbvie	M16-045	Atopic Dermatitis	Sub-I	3	04-Feb-26
Amgen	20210145	Atopic Dermatitis	Sub-I	3	26-Feb-26
TARGET-DERM	TARGET-DERM	Atopic Dermatitis	Sub-I	4	06-Apr-26
Janssen	95475939ADM2001	Atopic Dermatitis	Sub-I	2b	12-May-26
Roche	CS45943	Atopic Dermatitis	Sub-I	2	N/A
Abbvie	M16-047	Atopic Dermatitis	Sub-I	3	ONGOING
Abbvie	M17-380	Atopic Dermatitis	Sub-I	3	ONGOING
Aclaris	ATI-045-AD-201	Atopic Dermatitis	Sub-I	2b	ONGOING
Amgen	20210146	Atopic Dermatitis	Sub-I	3	ONGOING
Anacor	AN2728-AD-301-302-POST01	Atopic Dermatitis	Sub-I	OBS	ONGOING
Apogee	APG777-301	Atopic Dermatitis	Sub-I	3	ONGOING
Apollo	AP43CP04	Atopic Dermatitis	Sub-I	2b	ONGOING
CorEvitas	AD-550	Atopic Dermatitis	Sub-I	4	ONGOING

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Corrona	Corrona-AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Galderma	SPR207806	Atopic Dermatitis	Sub-I	OBS	ONGOING
Janssen	95597528ADM2001	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-KGCE	Atopic Dermatitis	Sub-I	4	ONGOING
Pfizer	B7451023	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	B7451031	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	C4531002	Atopic Dermatitis	Sub-I	2	ONGOING
Pfizer	C4531005	Atopic Dermatitis	Sub-I	3	ONGOING
Roche	CS45570	Atopic Dermatitis	Sub-I	2	ONGOING
Sanofi	EFC17599	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	EFC17600	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	LTS17367	Atopic Dermatitis	Sub-I	2/3	ONGOING
Attovia	ATTO-3712-101	Atopic Dermatitis	Sub-I	1	ONGOING
Enveda	ENV-294-202	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-B002	Atopic Dermatitis	Sub-I	4	ONGOING
Organon	OG0505-3104	Atopic Dermatitis	Sub-I	3	ONGOING
Triveni Bio	TRIV-509-101	Atopic Dermatitis	Sub-I	2a	ONGOING
Triveni Bio	TRIV-573-101	Atopic Dermatitis	Sub-I	2	ONGOING
Brickell	BBI-4000-CL-301	Axillary Hyperhidrosis	Sub-I	3	11-Aug-21
Akari	AK802	Bullous Pemphigoid	Sub-I	3	08-Sep-22
AstraZenaca	D325AC00002	Bullous Pemphigoid	Sub-I	3	31-Aug-23
Evommune	EVO756-CIU001	Chronic Inducible Urticaria	Sub-I	2a	20-Jun-25
Celldex	CDX0159-07	Chronic Inducible Urticaria	Sub-I	2	25-Nov-25
Sanofi	EFC16973	Chronic Pruritus of Unknown Origin	Sub-I	3	13-Nov-24
Galderma	SPR207913	Chronic Pruritus of Unknown Origin	Sub-I	2	ONGOING
Novartis	CLOU064R12301	Chronic Pruritus of Unknown Origin	Sub-I	3	ONGOING
Novartis	CQGE031C2302	Chronic Spontaneous Urticaria	Sub-I	3	30-Sep-22
Novartis	CQGE031C2302E1	Chronic Spontaneous Urticaria	Sub-I	3b	25-Oct-22
Celldex	CDX0159-02	Chronic Spontaneous Urticaria	Sub-I	1	10-Jan-23
Evidera	EVA-32391-01	Chronic Spontaneous Urticaria	Sub-I	OBS	13-Mar-23
Amgen	20190194	Chronic Spontaneous Urticaria	Sub-I	2b	20-Apr-23
Celldex	CDX0159-06	Chronic Spontaneous Urticaria	Sub-I	2	07-Nov-23
Escient	EP-262-201	Chronic Spontaneous Urticaria	Sub-I	2	26-Mar-25
InflaRX	INF904-P2.1	Chronic Spontaneous Urticaria	Sub-I	2a	04-Dec-25
Jasper Therapeutics	JSP-CP-011	Chronic Spontaneous Urticaria	Sub-I	2a	ONGOING
Jasper Therapeutics	JSP-CP-014	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Novartis	CLOU064AUS04	Chronic Spontaneous Urticaria	Sub-I	OBS	ONGOING
Blueprint Medicines	BLU-808-1201	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Celldex	CDX0159-12	Chronic Spontaneous Urticaria	Sub-I	3	ONGOING
Celldex	CDX0159-17	Chronic Spontaneous Urticaria	Sub-I	3b	ONGOING
Gilead	GS-US-497-5888	Cutaneous Lupus Erythematosus	Sub-I	1b	29-Nov-22
Biogen	230LE301	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Biogen	230LE305	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Merck	MS200569-0003	Cutaneous Lupus Erythematosus	Sub-I	2	16-Jan-25
Merck	MS200569-0048	Cutaneous Lupus Erythematosus	Sub-I	1	28-Jan-26
Gilead	GS-US-497-6486	Cutaneous Lupus Erythematosus	Sub-I	2a	19-May-26
Merck	MS504908_0008	Cutaneous Lupus Erythematosus	Sub-I	3	ONGOING
Ventus	VENT-03-201	Cutaneous Lupus Erythematosus	Sub-I	2a	ONGOING
Horizon	HZNP-DAX-202	Cutaneous Lupus Erythematosus	Sub-I	2	21-Nov-25
Nflection	NFX-179-NFI-202	Cutaneous Neurofibroma	Sub-I	2	16-Oct-23
Regeneron	R2810-ONC-2251	Cutaneous Squamous Cell Carcinoma	Sub-I	3	28-May-26
CastleBio Science	CBI_2019_cSCC_PVS_001	Cutaneous Squamous Cell Carcinoma	Sub-I	4	ONGOING
Elorac	EL-1007-01-01	Cutaneous T-Cell Lymphoma	Sub-I	3	20-Oct-22
Soligenix	HPN-CTCL-03-EUR	Cutaneous T-Cell Lymphoma	Sub-I	3	ONGOING
Celgene	CC-10004-PSOR-025	Genital Psoriasis	Sub-I	3	27-Apr-22
AnaptysBio	ANB019-401	GPP/PPP	Sub-I	3	02-Mar-23
Regeneron	R668-AD-1924	Hand/Foot Dermatitis	Sub-I	3	22-Feb-23
Lilly	J2T-MC-KGCD	Hand/Foot Dermatitis	Sub-I	3b	ONGOING
Pfizer	C2501007	Hidradenitis Suppurativa	Sub-I	2a	15-Feb-22
Abbvie	M20-040	Hidradenitis Suppurativa	Sub-I	2	15-Mar-22
Boehringer Ingelheim	1368-0052	Hidradenitis Suppurativa	Sub-I	2a	29-Mar-22
Novartis	CAIN457M2302	Hidradenitis Suppurativa	Sub-I	2/3	31-Oct-22
Boehringer Ingelheim	1368-0067	Hidradenitis Suppurativa	Sub-I	2	31-Jan-23
Janssen	77474462HDS2001	Hidradenitis Suppurativa	Sub-I	2	10-Feb-23
Moonlake	M1095-HS-201	Hidradenitis Suppurativa	Sub-I	2	02-Oct-23
Acelyrin	21102	Hidradenitis Suppurativa	Sub-I	2	16-Apr-24
Acelyrin	22107	Hidradenitis Suppurativa	Sub-I	3	26-Feb-25
Adelphi	AB6762B	Hidradenitis Suppurativa	Sub-I	OBS	01-Mar-25
Boehringer Ingelheim	1368-0098	Hidradenitis Suppurativa	Sub-I	2b/3	31-Jul-25
Novartis	CAIN457M2301E1	Hidradenitis Suppurativa	Sub-I	3	26-Aug-25
Incyte	INCB54707-302	Hidradenitis Suppurativa	Sub-I	3	23-Jan-26
Incyte	INCB54707-301	Hidradenitis Suppurativa	Sub-I	3	17-Feb-26
Sanofi	ACT17841	Hidradenitis Suppurativa	Sub-I	2	19-Feb-26
Moonlake	M1095-HS-304	Hidradenitis Suppurativa	Sub-I	3	21-May-26
Abbvie	M20-262	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Abbvie	M20-465	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Abbvie	M23-698	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Lilly	I7P-MC-DSAF	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Merck	MK7240-012	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Pfizer	B7981119	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Incyte	INCB054707-801	Hidradenitis Suppurativa	Sub-I	3b	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-303	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Novartis	CCFZ533H12201BC	Hidradenitis Suppurativa	Sub-I	2	ONGOING

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Novartis	CLOU064J12301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Mayne	18-ICH-001	Lamellar Ichthyosis	Sub-I	2	17-Jan-22
Timber	TMB01-301/MUST	Lamellar Ichthyosis	Sub-I	3	03-Dec-24
Priovant	PVT-2201-304	Lichen Planopilaris	Sub-I	2/3	ONGOING
Incyte	INCB18424-216	Lichen Planus	Sub-I	2	25-Apr-24
Novartis	CGIA362C12201	Lichen Planus	Sub-I	2	ONGOING
Evidera	EVA-36509-01	Lower Abdominal Fat	Sub-I	OBS	08-Nov-23
Evidera	EVA-36509-02	Lower Abdominal Fat	Sub-I	OBS	18-Jul-24
Evidera	EVA-36509-04	Lower Abdominal Fat	Sub-I	OBS	23-Jan-25
Evidera	EVA-36509-08	Lower Abdominal Fat	Sub-I	OBS	18-Sep-25
Evidera	146323-01	Lower Abdominal Fat	Sub-I	OBS	01-Nov-25
Evidera	152364-01	Lower Abdominal Fat	Sub-I	OBS	01-Jun-26
DermTech	17-06	Multi-Indication	Sub-I	4	17-Jun-24
Lilly	I1F-MC-B018	Nail Psoriasis	Sub-I	OBS	29-Jan-25
Quoin	CL-QRX003-001	Netherton Syndrome	Sub-I	2	08-Apr-26
BioCryst	BCX17725-101	Netherton Syndrome	Sub-I	1	ONGOING
Quoin	CL-QRX003-002	Netherton Syndrome	Sub-I	2	ONGOING
Quoin	CL-QRX003-004	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-005	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-006	Netherton Syndrome	Sub-I	3	ONGOING
DermTech	21-02	Normal Skin	Sub-I	4	29-Jan-24
Mindera	MND-24-MK-02	Normal Skin	Sub-I	1	30-Sep-25
Cara	CR845-210601	Notalgia Parasthetica	Sub-I	2	11-Aug-22
Evidera	EVA-37056-00	Notalgia Parasthetica	Sub-I	OBS	24-Apr-24
Cara	CR845-310601	Notalgia Parasthetica	Sub-I	2-3	02-Jul-24
Clexio	CLE400-NP-201	Notalgia Parasthetica	Sub-I	2	24-Jan-25
Abbvie	M15-994	Palmoplantar Psoriasis	Sub-I	3b	17-Jul-23
BMS	IM011-1112	Palmoplantar Psoriasis	Sub-I	4	02-Jul-25
Aristea	RIST4721-202	Palmoplantar Pustulosis	Sub-I	2	12-May-23
Dr. Reddy's	DFD-29-CD-004	Papulopustular Rosacea	Sub-I	3	24-Jul-23
Sanofi	EFC16459	Prurigo Nodularis	Sub-I	3	25-May-22
Galderma	RD.06.SPR.203065	Prurigo Nodularis	Sub-I	3	13-Jun-22
Galderma	RD.06.SPR.202699	Prurigo Nodularis	Sub-I	3	13-Jun-22
Incyte	INCB18424-110	Prurigo Nodularis	Sub-I	1	09-May-25
Galderma	SPR207807	Prurigo Nodularis	Sub-I	OBS	ONGOING
InnoCare	ICP-CL-00609	Prurigo Nodularis	Sub-I	2	ONGOING
Sanofi	OBS17721	Prurigo Nodularis	Sub-I	4	ONGOING
Boehringer Ingelheim	1407-0005	Psoriasis	Sub-I	2	21-Oct-21
Lilly	F1P-MC-KFAC	Psoriasis	Sub-I	1	03-Nov-21
Lilly	I6T-MC-AMAH	Psoriasis	Sub-I	3	28-Apr-22
Amgen	20190232	Psoriasis	Sub-I	3	08-Sep-22
Janssen	77242113PSO2001	Psoriasis	Sub-I	2b	28-Sep-22
Abbvie	M19-164	Psoriasis	Sub-I	3b	29-Sep-22

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Abbvie	M19-164 Companion	Psoriasis	Sub-I	3b	29-Sep-22
Aurigene	AUR101-202	Psoriasis	Sub-I	2	12-Oct-22
Arcutis	ARQ-151-311	Psoriasis	Sub-I	3	08-Nov-22
Nimbus	4858-201	Psoriasis	Sub-I	2b	05-Dec-22
Biocon	BIO-USTEKI-305	Psoriasis	Sub-I	3	20-Dec-22
Janssen	77242113PSO2002	Psoriasis	Sub-I	2b	23-Jan-23
Abbvie	M15-997	Psoriasis	Sub-I	3	20-Mar-23
Abbvie	M18-816	Psoriasis	Sub-I	2	20-Mar-23
Abbott (ESPRIT)	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
Abbott (ESPRIT)	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
PSOLAR	C0168Z03	Psoriasis	Sub-I	OBS	18-May-23
Abbvie	M20-326	Psoriasis	Sub-I	4	17-Jul-23
Celgene	CC-10004-PPSO-003	Psoriasis	Sub-I	3	03-Aug-23
Biocon	BM12H-PSO-03-G-02	Psoriasis	Sub-I	3	11-Jan-24
Ventyx	VTX958-201	Psoriasis	Sub-I	2	13-Feb-24
Janssen	77242113PSO3001	Psoriasis	Sub-I	3	19-Mar-24
DICE Therapeutics	DCE806201	Psoriasis	Sub-I	2	28-Mar-24
Mindera	MND-21-MKPs-02	Psoriasis	Sub-I	4	28-May-24
LITE	PCS-1608-35830	Psoriasis	Sub-I	2/3	05-Jul-24
UCB	PS0020	Psoriasis	Sub-I	2	17-Jul-24
Sanofi	DRI17849	Psoriasis	Sub-I	2	03-Dec-24
Janssen	77242113PSO3003	Psoriasis	Sub-I	3	14-Jan-25
Janssen	77242113PSO3002	Psoriasis	Sub-I	3	20-Feb-25
BMS	IM011-075	Psoriasis	Sub-I	3b	06-May-25
Janssen	CNT01959PSO3018	Psoriasis	Sub-I	3b	10-Sep-25
Takeda	TAK279-3001	Psoriasis	Sub-I	3	20-Jan-26
Alumis	ESK-001-016	Psoriasis	Sub-I	3	17-Feb-26
Dermavant	DMVT-505-3004	Psoriasis	Sub-I	3	11-Mar-26
Celgene	CC-10004-PPSO-004	Psoriasis	Sub-I	3b	24-Mar-26
Abbvie	M24-541	Psoriasis	Sub-I	4	02-Jun-26
Takeda	TAK-279-PsO-3004	Psoriasis	Sub-I	3	02-Jun-26
Amgen	20200196	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1128	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1130	Psoriasis	Sub-I	3b/4	ONGOING
CorEvitas	CorEvitas-PSO-505	Psoriasis	Sub-I	OBS	ONGOING
Corrona	Corrona-PSO-550	Psoriasis	Sub-I	4	ONGOING
Lilly	I1F-MC-RHDC	Psoriasis	Sub-I	3b	ONGOING
Lilly	I1F-MC-RHDD	Psoriasis	Sub-I	3b	ONGOING
UCB	PS0021	Psoriasis	Sub-I	3	ONGOING
UPENN	CP3	Psoriasis	Sub-I	4	ONGOING
Alumis	ESK-001-018	Psoriasis	Sub-I	3	ONGOING
InventisBio	D2570-207	Psoriasis	Sub-I	2	ONGOING
Takeda	TAK279-3003	Psoriasis	Sub-I	3	ONGOING

Michael J. Isaacs, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Abcentra	ORT-2020-01	Psoriasis	Sub-I	2	21-Feb-23
Novartis	CAIN457P12302	Psoriatic Arthritis	Sub-I	3	12-Sep-22
Nimbus	4858-202	Psoriatic Arthritis	Sub-I	2b	29-Mar-23
Novartis	CAIN457A02001B	Psoriatic Arthritis	Sub-I	4	23-Jan-25
Boehringer Ingelheim	1368-0140	Pyoderma Gangrenosum	Sub-I	3	ONGOING
Evidera	EVA-20371-01	Scalp Psoriasis	Sub-I	OBS	11-Jan-24
BMS	IM011-220	Scalp Psoriasis	Sub-I	3b/4	19-Nov-24
Arcutis	ARQ-154-304	Seborrheic Dermatitis	Sub-I	3	06-Jul-22
Evidera	EVA-44850	Skin Tone Assessment	Sub-I	OBS	ONGOING
Evidera	EVA-31203-01	Vitiligo	Sub-I	OBS	31-Oct-22
Abbvie	M19-051	Vitiligo	Sub-I	2	09-Nov-23
Merck	MK-6194-007	Vitiligo	Sub-I	2a	20-May-25
VYNE	VY2024-02	Vitiligo	Sub-I	2b	30-Jul-25
Pfizer	B7981080	Vitiligo	Sub-I	3	10-Sep-25
Pfizer	B7981040	Vitiligo	Sub-I	3	05-Mar-26
Abbvie	M19-044	Vitiligo	Sub-I	3	ONGOING
Abbvie	M25-264	Vitiligo	Sub-I	3	ONGOING
Lilly	J5D-MC-FPAD	Vitiligo	Sub-I	2	ONGOING
Pfizer	B7981041	Vitiligo	Sub-I	3	ONGOING
Novartis	CGIA362B12201	Vitiligo	Sub-I	2	ONGOING